Nutrition Metabolism and Cardiovascular Diseases最新文献

{"title":"SPECIAL ISSUE ON NEW INSIGHTS INTO CARDIOVASCULAR RISK MANAGEMENT","authors":"","doi":"10.1016/S0939-4753(25)00105-X","DOIUrl":"10.1016/S0939-4753(25)00105-X","url":null,"abstract":"","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103951"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?","authors":"Alessandro Maloberti ,&nbsp;Valentina Colombo ,&nbsp;Francesca Daus ,&nbsp;Lorenzo De Censi ,&nbsp;Maurizio Giuseppe Abrignani ,&nbsp;Pier Luigi Temporelli ,&nbsp;Giulio Binaghi ,&nbsp;Furio Colivicchi ,&nbsp;Massimo Grimaldi ,&nbsp;Domenico Gabrielli ,&nbsp;Claudio Borghi ,&nbsp;Fabrizio Oliva","doi":"10.1016/j.numecd.2024.103792","DOIUrl":"10.1016/j.numecd.2024.103792","url":null,"abstract":"<div><h3>Aims</h3><div>The most frequent consequence of elevated uric acid (UA) levels is the development of gout and urate kidney disease. Besides these effects, several studies have investigated the association between hyperuricemia and cardiovascular (CV) disease. High serum UA has been identified as an important determinant of all-cause and CV mortality and CV events (acute and chronic coronary syndrome, stroke and peripheral artery disease).</div><div>Despite the high number of publications on this topic, there are two questions that are still unanswered: do we need a specific CV cut-off of serum UA to better refine the CV risk? Is urate lowering treatment (ULT) able to reduce CV risk in asymptomatic patients? In this review, we will focus on these two points.</div></div><div><h3>Data synthesis</h3><div>Although no doubt exists that the relationship between CV events starts at lower levels than the actually used cut-off, different papers found dissimilar cut-offs. Furthermore, heterogeneity is present depending on the specific CV events evaluated and none of the found cut-off have been tested in external populations (in order to confirm its discriminatory capacity). Furthermore, only few randomized clinical trials on the role of hypouricemic agents in reducing the CV risk have been published giving heterogeneous results. The last published one (ALL-HEART) has strong limitations, that we will deeply discuss.</div></div><div><h3>Conclusions</h3><div>A definitive answer to the two questions is impossible with the actually published paper but, over identifying current gaps in knowledge we try to individuate how they can be overruled.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103792"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic inflammation response index and carotid atherosclerosis incidence in the Chinese population: A retrospective cohort study","authors":"Wenqing Nai ,&nbsp;Li Lei ,&nbsp;Qiuxia Zhang ,&nbsp;Shaohua Yan ,&nbsp;JieLing Xu ,&nbsp;Lixia Lin ,&nbsp;Wei Luo ,&nbsp;Siyu Chen ,&nbsp;Xiaocong Liu ,&nbsp;Yanbin Gao ,&nbsp;Shiping Cao ,&nbsp;Jiancheng Xiu","doi":"10.1016/j.numecd.2024.103787","DOIUrl":"10.1016/j.numecd.2024.103787","url":null,"abstract":"<div><h3>Background and aim</h3><div>The relationship between the systemic inflammatory response index (SIRI) and carotid atherosclerosis has not yet been assessed in a longitudinal investigation. Our current study aimed to investigate whether SIRI is related to an increased risk of incident carotid plaque.</div></div><div><h3>Methods and results</h3><div>Our study included individuals who did not have carotid atherosclerosis and had undergone yearly health check-ups at the Department of Health Management of Nanfang Hospital between 2011 and 2018 (total n = 3927). SIRI was computed by a composite value of neutrophils, monocytes, and lymphocytes. Over a median follow-up time of 4.42 years, 872 (22.21 %) participants developed carotid plaque in the entire cohort. The adjusted hazard ratio (HR) for the continuous SIRI was 1.093 (95 % CI: 1.021–1.223) in our present study. In the general population, individuals belonging to the highest quartile of SIRI had an elevated risk of carotid plaque, as compared to those within the lowest quartile (HR 1.122, 95 % CI: 1.011–1.391, P for trend = 0.041). Furthermore, this trend was even more pronounced among participants without hypertension, diabetes and hyperlipidemia in the highest SIRI quartile, who demonstrated a markedly increased risk of carotid plaque when contrasted with those in the lowest quartile (HR 1.277, 95 % CI: 1.041–1.568, P for trend = 0.006).</div></div><div><h3>Conclusions</h3><div>Our research findings suggest an association between increased SIRI levels and a higher incidence of carotid atherosclerosis, especially among the people without a history of hypertension, diabetes and hyperlipidemia.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103787"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Naples Prognostic Score with cardiovascular disease risk and its longitudinal prognostic impact on mortality in cardiovascular disease patients: Evidence from NHANES","authors":"Guike Lai ,&nbsp;Yipin Zhao ,&nbsp;Cuiling Yang ,&nbsp;Yuanyuan Zheng ,&nbsp;Jingjing Sun ,&nbsp;Yingjie Zhao ,&nbsp;MingGe Ding","doi":"10.1016/j.numecd.2024.103840","DOIUrl":"10.1016/j.numecd.2024.103840","url":null,"abstract":"<div><h3>Background and aim</h3><div>The Naples Prognostic Score (NPS) predicts outcomes in various diseases, but its impact on cardiovascular disease (CVD) is understudied. This study investigates the association between NPS and CVD prevalence and mortality among US adults.</div></div><div><h3>Methods and results</h3><div>This study utilized data from the Continuous National Health and Nutrition Examination Survey (NHANES) conducted between 1999 and 2016, with mortality follow-up data available through December 31, 2019. NPS was calculated using serum albumin, total cholesterol, neutrophil to lymphocyte ratio, and lymphocyte to monocyte ratio. Participants were stratified into low, moderate, and high NPS groups. Multiple logistic regression estimated odds ratios (OR) for CVD prevalence, while Cox proportional regression estimated hazard ratios (HR) for mortality. Of 39,572 participants, 20.24 % were in the low group, 69.79 % in the moderate group, and 9.96 % in the high group. After adjusting for confounders, the CVD prevalence ORs for moderate and high groups were 1.19 (95 % CI: 1.05, 1.34) and 1.78 (95 % CI: 1.53, 2.07), respectively (<em>P</em> for trend &lt;0.001). Compared to the low group, the high group had adjusted HRs of 1.92 (95 % CI: 1.54, 2.41) for all-cause mortality, 1.61 (95 % CI: 1.12, 2.34) for cardiovascular mortality, and 1.83 (95 % CI: 1.11, 3.02) for cancer-related mortality (all <em>P</em> for trend &lt;0.01). These associations remained significant across all subgroups.</div></div><div><h3>Conclusion</h3><div>NPS is an independent risk factor for CVD and is positively associated with all-cause and cardiovascular mortality in individuals with CVD.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103840"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is MAFLD better than NAFLD in predicting the risk of major cardiovascular diseases? Evidence from a 7-year prospective cohort study","authors":"Xue Wang ,&nbsp;Jinlong You ,&nbsp;Jing Tang ,&nbsp;Xiuqian Li ,&nbsp;Rui Wang ,&nbsp;Yuanyuan Li ,&nbsp;Chun Yin ,&nbsp;Yana Bai ,&nbsp;Minzhen Wang ,&nbsp;Shan Zheng","doi":"10.1016/j.numecd.2024.103799","DOIUrl":"10.1016/j.numecd.2024.103799","url":null,"abstract":"<div><h3>Background and aims</h3><div>Whether the new standard of metabolic dysfunction-associated fatty liver disease (MAFLD) has more pronounced clinical and population screening diagnostic value than nonalcoholic fatty liver disease (NAFLD) is unclear. This study evaluated the utility of MAFLD and NAFLD for predicting major cardiovascular disease (CVD) risk.</div></div><div><h3>Methods and results</h3><div>A prospective cohort study approach was utilized to collect 19,399 study participants without CVD at baseline who completed follow-up from the Jinchang cohort platform during 2011–2017. According to clinical ultrasonic diagnosis results and disease diagnosis criteria, the baseline population was divided into MAFLD, NAFLD, Both-FLD and No-FLD groups. Based on the multifactorial Cox proportional risk model to analyze the relationship between three kinds of patients and CVD, the score prediction model of CVD was constructed with reference to the Framingham Risk Score (FRS) and the model was evaluated. Compared with No-FLD, the HRs and 95 % CIs for the risk of CVD development in patients with NAFLD, MAFLD, and Both-FLD were 1.54 (1.34–1.76), 1.57 (1.37–1.79), and 1.62 (1.41–1.87), in that order. The scoring model showed a range of 5.90%–84.59 % risk of CVD in the three groups. As the risk score increased, the risk of developing CVD gradually increased. Evaluation metrics of all three models in the training set and validation set showed that the models have good prediction efficacy.</div></div><div><h3>Conclusion</h3><div>In terms of CVD risk and prognosis, MAFLD had no advantage over NAFLD. However, Both-FLD was found to predict a higher risk of CVD and to have superior predictive efficacy.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103799"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease","authors":"Rui Dong ,&nbsp;Ting Tian ,&nbsp;Zhenghan Luo ,&nbsp;Dongchun Chang ,&nbsp;Hong Xue ,&nbsp;Sen Qu ,&nbsp;Jia Wang ,&nbsp;Chao Shen ,&nbsp;Ru Zhang ,&nbsp;Jie Wang","doi":"10.1016/j.numecd.2024.103797","DOIUrl":"10.1016/j.numecd.2024.103797","url":null,"abstract":"<div><h3>Background and aims</h3><div>Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) often manifest a combination of cardiometabolic risk factors of varying severity. The cardiometabolic phenotypes and their associations with advanced liver fibrosis and all-cause mortality among patients with MASLD warrant further investigation.</div></div><div><h3>Methods and results</h3><div>A total of 4209 and 1901 eligible participants were obtained from the National Health and Nutrition Examination Survey and included in the original and replication datasets, respectively. In the original dataset, three distinct and stable cardiometabolic phenotypes were identified using unsupervised cluster analyses, including mild cardiometabolic risk factor (MCMRF) phenotype, overweight combined with high diastolic blood pressure dominated (OCHBP) phenotype, and severe glucose and lipid metabolic dysfunction dominated (SGLMD) phenotype. The above phenotypes were subsequently replicated in the replication dataset, demonstrating similar characteristics. After adjusting for potential covariates, the results of logistic and Cox regression models showed that OCHBP and SGLMD phenotypes were significantly associated with higher odds of advanced liver fibrosis (OCHBP: OR = 4.37, 95 % CI: 1.54–12.35, <em>P</em> = 0.020; SGLMD: OR = 9.66, 95 % CI: 4.76–19.61, <em>P</em> = 0.002) and an increased risk of all-cause mortality (OCHBP: HR = 1.39, 95 % CI: 1.17–1.65, <em>P</em> &lt; 0.001; SGLMD: HR = 2.51, 95 % CI: 1.86–3.40, <em>P</em> &lt; 0.001) compared to the MCMRF phenotype. Moreover, the observed associations remained statistically significant in most subgroups, and a series of sensitivity analyses further confirmed the robustness of these findings.</div></div><div><h3>Conclusion</h3><div>Three heterogeneous cardiometabolic phenotypes were identified among participants with MASLD, showing significant associations with two critical outcomes. These novel phenotypes may be of great importance to precision medicine in MASLD.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103797"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperuricemia, A new cardiovascular risk","authors":"Masanari Kuwabara ,&nbsp;Ichiro Hisatome ,&nbsp;Ryusuke Ae ,&nbsp;Koki Kosami ,&nbsp;Yuhei Aoki ,&nbsp;Ana Andres-Hernando ,&nbsp;Mehmet Kanbay ,&nbsp;Miguel A. Lanaspa","doi":"10.1016/j.numecd.2024.103796","DOIUrl":"10.1016/j.numecd.2024.103796","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hyperuricemia is strongly linked to increased cardiovascular risk, including hypertension, coronary artery disease, arrythmia, and heart failure. Uric acid, as the end-product of purine metabolism, plays a critical role in cellular processes, but elevated levels can drive inflammation and oxidative stress. This review aims to emphasize the robust association between hyperuricemia and cardiovascular diseases, exploring whether uric acid-lowering therapies can mitigate cardiovascular events and improve patient outcomes.</div></div><div><h3>Methods and results</h3><div>A comprehensive review of PubMed sources was conducted, underscoring the significant link between high uric acid levels and cardiovascular events, particularly in patients with gout. Gender differences were observed, where premenopausal women have lower uric acid levels, likely due to hormonal effects, suggesting the potential need for gender-specific definitions in assessing cardiovascular risk. Epidemiological studies demonstrate a consistent correlation between hyperuricemia and adverse cardiovascular outcomes. However, interventional trials using xanthine oxidase inhibitors, such as allopurinol and febuxostat, have shown mixed results regarding their impact on reducing cardiovascular events. Additionally, emerging evidence suggests a \"xanthine oxidase withdrawal syndrome\" upon discontinuation of these therapies, highlighting the need for cautious management.</div></div><div><h3>Conclusion</h3><div>The strong association between elevated uric acid levels and cardiovascular diseases is well-documented. While lowering uric acid shows potential for reducing cardiovascular risk, current evidence from interventional trials remains inconclusive. Future research should focus on patient-specific therapeutic strategies, particularly for those at high cardiovascular risk with hyperuricemia and/or gout, to better define the benefits of targeted treatments.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 3","pages":"Article 103796"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific optimal cut-off points for metabolic health indicators to predict incident type 2 diabetes mellitus.","authors":"Zailing Xing, Mianli Xiao, Douglas D Schocken, Janice C Zgibor, Amy C Alman","doi":"10.1016/j.numecd.2025.103963","DOIUrl":"https://doi.org/10.1016/j.numecd.2025.103963","url":null,"abstract":"<p><strong>Background and aim: </strong>We aimed to determine the optimal cut-off points for metabolic health indicators, including insulin resistance (IR), glucose, insulin, BMI, and waist circumference, in middle-aged nondiabetic people to predict future type 2 diabetes mellitus (T2DM).</p><p><strong>Methods and results: </strong>The data came from 12,543 Atherosclerosis Risk Communities Study participants, including 5758 men and 6785 women. They did not have diabetes at baseline and were followed for incident T2DM within 3, 6, and 9 years. IR was estimated using four IR metrics: HOMA-IR, METS-IR, TyG index, and TG/HDL-C. We used the Youden index to determine the optimal cut-off values. In females, the cut-off points for glucose to predict incident T2DM ranged from 96 to 102 mg/dL, with Area Under the Curve (AUC) values of 0.64-0.85. In males, the cut-off points ranged from 102 to 106 mg/dL, with AUC values of 0.60-0.83. For HOMA-IR, the cut-off points in females varied from 2.4 to 3.2, with AUC values of 0.69-0.78, while they ranged from 2.8 to 3.2 in males. The optimal cut-off values for METS-IR, TyG index, TG/HDL-C, insulin, BMI, and waist circumference were 40-43, 8.6-8.9, 2.0-3.2, 9-15 μU/mL, 28-29 kg/m², and 91-97 cm in women, and 44-45, 8.8-8.9, 2.9-3.2, 11-12 μU/mL, 27-29 kg/m², and 99-103 cm in men.</p><p><strong>Conclusions: </strong>The optimal threshold for each predictor's prediction of incident T2DM varied by sex. The eight predictors' order of predictive performance were fasting glucose, HOMA-IR, METS-IR, insulin, BMI, waist circumference, TyG index, and TG/HDL-C.</p>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":" ","pages":"103963"},"PeriodicalIF":3.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutrition and dietary interventions for treatment and management of familial hypercholesterolaemia in children and adolescents: A systematic review.","authors":"Kerryn W Chisholm, Hiba Jebeile, Maddison J Henderson, Sasha Lorien, Shubha Srinivasan, Natalie Lister","doi":"10.1016/j.numecd.2025.103967","DOIUrl":"https://doi.org/10.1016/j.numecd.2025.103967","url":null,"abstract":"<p><strong>Aims: </strong>Familial hypercholesterolaemia (FH) is a common inherited metabolic disease caused by mutations of genes involved in low-density cholesterol (LDL-C) catabolism. The accumulation of LDL-C increases the risk of early atherosclerosis and premature coronary artery disease. The aim of this systematic review was to investigate the impact of dietary interventions to lower total cholesterol (TC) and LDL-C in FH children not on medication.</p><p><strong>Data synthesis: </strong>We searched three databases to March 2024 to identify randomised-controlled trials (RCTs), crossover and non-randomised observational studies of dietary interventions conducted in children and adolescents, 2-<19 years, with FH and measuring TC and LDL-C pre- and post-intervention. Twenty-eight studies were found, testing interventions with modified percent of energy from fat, change in type of fat consumed, functional foods e.g., plant sterols, fibre and modification of specific nutrients. 8 studies using plant sterols (1.21 ± 0.13-2.76 ± 0.15g/day) demonstrated significant LDL-C reductions ranging from 10 to 18 % compared to control groups. Modifying fat content using rapeseed oil (59 % monounsaturated fat @15g/day) showed a 7 % reduction in LDL-C. 7 studies of functional foods showed reductions in LDL -C ranging from 4 % (calcium carbonate) to 27.5 % after consumption of pulverized blueberry tea with 32 mg/kg anthocyanins. 6 studies of dietary counselling interventions reported reductions in LDL-C from 3 to 22 %.</p><p><strong>Conclusions: </strong>The addition of plant sterols had a significant cholesterol-lowering effect for children with FH from age 5. Additional studies are needed to investigate the efficacy of all other dietary interventions.</p><p><strong>Registry number: </strong>PROSPERO (CRD42023392111).</p>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":" ","pages":"103967"},"PeriodicalIF":3.3,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality","authors":"Jung-Hwan Kim ,&nbsp;Yaeji Lee ,&nbsp;Chung-Mo Nam ,&nbsp;Yu-Jin Kwon ,&nbsp;Ji-Won Lee","doi":"10.1016/j.numecd.2025.103965","DOIUrl":"10.1016/j.numecd.2025.103965","url":null,"abstract":"<div><h3>Background and aims</h3><div>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a potential independent risk factor for cardiovascular disease (CVD)-associated and all-cause mortalities as they share common risk factors. We investigated the association between cardiometabolic risk factors for MASLD and CVD-associated and all-cause mortality risks in middle-aged and older Korean adults.</div></div><div><h3>Methods and results</h3><div>We used data from the Korean Genome and Epidemiology Study, a population-based prospective cohort study. Five cardiometabolic risk factors were assessed. MASLD was defined as liver steatosis with a fatty liver index (FLI) ≥60 and at least one cardiometabolic risk factor. The non-MASLD group included individuals with a FLI &lt;60 or FLI ≥60 without cardiometabolic risk factors. The primary outcomes were CVD-associated and all-cause mortalities. Cox proportional hazard models were used to evaluate the association between cardiometabolic risk factors for MASLD and mortalities, adjusting for covariates. Multivariable Cox regression analysis revealed that the MASLD group had increased CVD-associated and all-cause mortality risks compared to the non-MASLD group. The presence of three or more and one or more cardiometabolic risk factors significantly increased the CVD-associated and all-cause mortality rate, respectively. The combination of hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and high glucose concentrations significantly increased both CVD-associated (hazard ratio [HR] 3.64; 95 % confidence interval [CI] 1.44–9.22; p = 0.006) and all-cause (HR 4.57; 95 % CI: 1.74–12.05; p = 0.002) mortality risks.</div></div><div><h3>Conclusion</h3><div>Cardiometabolic risk factors for MASLD are strongly associated with higher CVD-associated and all-cause mortality risks, highlighting the need to manage hypertriglyceridemia, low HDL-C, and high glucose concentrations.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"35 6","pages":"Article 103965"},"PeriodicalIF":3.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}